Nucleix Nabs CE Mark for Bladder EpiCheck

Mar 22, 2017

|

NEW YORK (GenomeWeb) – Nucleix said today that it has received a CE Mark for its Bladder EpiCheck test, which is intended to help urologists better monitor bladder cancer patients.

Bladder EpiCheck is a urine test that utilizes multiplexed real-time PCR to analyze a panel of 15 methylation markers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Nucleix Nabs CE Mark for Bladder EpiCheck

To read the full story....

Breaking News

BARDA Awards $684K to Luminex for Enhanced COVID-19 Multiplex Antibody Test

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

What's Popular?

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Illumina to Acquire Grail for $8B in Cash and Stock

Biocept Lung Cancer Liquid Biopsy Test Obtains Coverage From Blue Cross Affiliate Highmark

Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

Sponsorships